Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Koirala, Pratistha ^a   Roth, Michael E ^a   Gill, Jonathan ^a   Piperdi, Sajida ^a   Chinai, Jordan M ^a   Geller, David S ^a   Hoang, Bang H ^a   Park, Amy ^a   Fremed, Michael A ^a,b   Zang, Xingxing ^a   Gorlick, Richard ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

BIOSYNTHESIS; BREAST TUMOR; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOLOGY; MACROPHAGE; MCF-7 CELL LINE; MORTALITY; NATURAL KILLER CELL; OSTEOSARCOMA; PATHOLOGY; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

B7-H1 ANTIGEN; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DENDRITIC CELLS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MCF-7 CELLS; OSTEOSARCOMA; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84979609883     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30093     Document Type: Article

References (63)

1. Damron, T. A., Ward, W. G. & Stewart, A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. 459, 40-47, doi: 10.1097/BLO.0b013e318059b8c9 (2007).
2. Sweetnam, R. Osteosarcoma. Br J Hosp Med. 28(112), 116-121 (1982).
3. Ottaviani, G. & Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat Res. 152, 3-13, doi: 10.1007/978-1-4419-0284-9-1 (2009).
4. Carrle, D. & Bielack, S. Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res. 152, 165-184, doi: 10.1007/978-1-4419-0284-9-8 (2009).
5. Harting, M. T. & Blakely, M. L. Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg. 15, 25-29, doi: 10.1053/j. sempedsurg.2005.11.005 (2006).
6. Link, M. P. et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 314, 1600-1606, doi: 10.1056/NEJM198606193142502 (1986).
7. Meyers, P. A. et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 117, 1736-1744, doi: 10.1002/cncr.25744 (2011).
8. Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115, 1531-1543, doi: 10.1002/cncr.24121 (2009).
9. Bielack, S. S. et al. Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol. 27, 557-565, doi: 10.1200/JCO.2008.16.2305 (2009).
10. Hawkins, D. S. & Arndt, C. A. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 98, 2447-2456, doi: 10.1002/cncr.11799 (2003).
11. Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 14, 1014-1022, doi: 10.1038/ni.2703 (2013).
12. Finn, O. J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 23 Suppl 8, viii6-9, doi: 10.1093/annonc/mds256 (2012).
13. Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883-899, doi: 10.1016/j.cell.2010.01.025 (2010).
14. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570, doi: 10.1126/science.1203486 (2011).
15. Champiat, S., Ferte, C., Lebel-Binay, S., Eggermont, A. & Soria, J. C. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 3, e27817, doi: 10.4161/onci.27817 (2014).
16. Broadhead, M. L., Clark, J. C., Myers, D. E., Dass, C. R. & Choong, P. F. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011, 959248, doi: 10.1155/2011/959248 (2011).
17. Gorlick, R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 152, 467-478, doi: 10.1007/978-1-4419-0284-9-27 (2009).
18. Kansara, M., Teng, M. W., Smyth, M. J. & Thomas, D. M. Translational biology of osteosarcoma. Nat Rev Cancer 14, 722-735, doi: 10.1038/nrc3838 (2014).
19. Jones, M. J. & Jallepalli, P. V. Chromothripsis: chromosomes in crisis. Dev Cell 23, 908-917, doi: 10.1016/j.devcel.2012.10.010 (2012).
20. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40, doi: 10.1016/j.cell.2010.11.055 (2011).
21. Chen, X. et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7, 104-112, doi: 10.1016/j.celrep.2014.03.003 (2014).
22. Lussier, D. M. et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 38, 96-106, doi: 10.1097/CJI.0000000000000065 (2015).
23. Shen, J. K. et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2, 690-698, doi: 10.1158/2326-6066.CIR-13-0224 (2014).
24. Carreno, B. M. & Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 20, 29-53, doi: 10.1146/annurev.immunol.20.091101.091806 (2002).
25. Dong, H. & Chen, L. B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) 81, 281-287, doi: 10.1007/s00109-003-0430-2 (2003).
26. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26, 677-704, doi: 10.1146/annurev.immunol.26.021607.090331 (2008).
27. Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372, 311-319, doi: 10.1056/NEJMoa1411087 (2015).
28. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372, 2018-2028, doi: 10.1056/NEJMoa1501824 (2015).
29. McDermott, D. F. & Atkins, M. B. PD-1 as a potential target in cancer therapy. Cancer Med. 2, 662-673, doi: 10.1002/cam4.106 (2013).
30. Mullard, A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov. 12, 489-492, doi: 10.1038/nrd4066 (2013).
31. Swaika, A., Hammond, W. A. & Joseph, R. W. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Mol Immunol. 67, 4-17, doi: 10.1016/j.molimm.2015.02.009 (2015).
32. Afanasiev, O. K. et al. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res. 19, 5351-5360, doi: 10.1158/1078-0432.CCR-13-0035 (2013).
33. Chen, B. J. et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 19, 3462-3473, doi: 10.1158/1078-0432.CCR-13-0855 (2013).
34. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567, doi: 10.1038/nature14011 (2014).
35. Wimberly, H. et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res. 3, 326-332, doi: 10.1158/2326-6066.CIR-14-0133 (2015).
36. Lussier, D. M., Johnson, J. L., Hingorani, P. & Blattman, J. N. Combination immunotherapy with alpha-CTLA-4 and alpha-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 3, 21, doi: 10.1186/s40425-015-0067-z (2015).
37. Chen, D. S., Irving, B. A. & Hodi, F. S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 18, 6580-6587, doi: 10.1158/1078-0432.CCR-12-1362 (2012).
38. Zhang, Q. W. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One 7, e50946, doi: 10.1371/journal.pone.0050946 (2012).
39. Gwak, J. M., Jang, M. H., Kim, D. I., Seo, A. N. & Park, S. Y. Prognostic value of tumor-associated macrophages according to histologic locations and hormone receptor status in breast cancer. PLoS One 10, e0125728, doi: 10.1371/journal.pone.0125728 (2015).
40. Laoui, D. et al. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol. 55, 861-867, doi: 10.1387/ijdb.113371dl (2011).
41. Leek, R. D. et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 56, 4625-4629 (1996).
42. Quatromoni, J. G. & Eruslanov, E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res. 4, 376-389 (2012).
43. Jersmann, H. P. Time to abandon dogma: CD14 is expressed by non-myeloid lineage cells. Immunol Cell Biol. 83, 462-467, doi: 10.1111/j.1440-1711.2005.01370.x (2005).
44. Buddingh, E. P. et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 17, 2110-2119, doi: 10.1158/1078-0432.CCR-10-2047 (2011).
45. Kleinerman, E. S. et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 10, 1310-1316 (1992).
46. Pahl, J. H. et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-gamma. J Exp Clin Cancer Res. 33, 27, doi: 10.1186/1756-9966-33-27 (2014).
47. Endo-Munoz, L., Evdokiou, A. & Saunders, N. A. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta 1826, 434-442, doi: 10.1016/j.bbcan.2012.07.003 (2012).
48. Endo-Munoz, L. et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 70, 7063-7072, doi: 10.1158/0008-5472.CAN-09-4291 (2010).
49. Avnet, S. et al. Increased osteoclast activity is associated with aggressiveness of osteosarcoma. Int J Oncol. 33, 1231-1238 (2008).
50. Akiyama, T. et al. Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts. J Pharm Pharmacol. 62, 470-476, doi: 10.1211/jpp/62.04.0009 (2010).
51. Fang, X., Jiang, C. & Xia, Q. Effectiveness evaluation of dendritic cell immunotherapy for osteosarcoma on survival rate and in vitro immune response. Genet Mol Res. 14, 11763-11770, doi: 10.4238/2015.October.2.10 (2015).
52. Himoudi, N. et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol. 14, 271-279, doi: 10.1007/s12094-012-0795-1 (2012).
53. Kawano, M., Nishida, H., Nakamoto, Y., Tsumura, H. & Tsuchiya, H. Cryoimmunologic antitumor effects enhanced by dendritic cells in osteosarcoma. Clin Orthop Relat Res. 468, 1373-1383, doi: 10.1007/s11999-010-1302-z (2010).
54. Kawano, M. et al. Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma. Oncol Rep. 34, 1995-2001, doi: 10.3892/or.2015.4161 (2015).
55. Muraro, M. et al. Interactions between osteosarcoma cell lines and dendritic cells immune function: An in vitro study. Cell Immunol. 253, 71-80, doi: 10.1016/j.cellimm.2008.05.002 (2008).
56. Edwards, J. R. et al. Lymphatics and bone. Hum Pathol. 39, 49-55, doi: 10.1016/j.humpath.2007.04.022 (2008).
57. Bacci, G. et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 14, 1126-1134 (2003).
58. Hattori, H. & Yamamoto, K. Lymph node metastasis of osteosarcoma. J Clin Oncol 30, e345-e349, doi: 10.1200/JCO.2012.42.3384 (2012).
59. Sowers, R. et al. Impairment of Methotrexate Transport Is Common in Osteosarcoma Tumor Samples. Sarcoma 2011, 834170, doi: 10.1155/2011/834170 (2011).
60. Abdeen, A. et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 115, 5243-5250, doi: 10.1002/cncr.24562 (2009).
61. Osborne, T. S. et al. Evaluation of eIF4E Expression in an Osteosarcoma Specific Tissue Microarray. Journal of pediatric hematology/oncology 33, 524-528, doi: 10.1097/MPH.0b013e318223d0c1 (2011).
62. Roth, M. et al. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer 63, 32-38, doi: 10.1002/pbc.25688 (2016).
63. Kubo, T. et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 112, 2119-2129, doi: 10.1002/cncr.23437 (2008).